Here is an overview on what the numbers suggest is the one of the cheapest robotic medical device manufacturers today, Stereotaxis (NASDAQ: STXS). Look for revenue growth to resume for STXS in 2014 and beyond driven by entry into Japan as well as VDrive approval helping close significant discount to peers.
Stereotaxis Raised Capital At Significantly Higher Valuations When It Was A Private Company When Growth Expectations Were High But Overall Sales Were Low. Look For Expectations For Growth To Resume Off Significantly Higher Revenue Base Which Should Drive Valuation Higher Once Again As Balance Sheet No Longer At Risk.
Before Stereotaxis went public in 2004, it raised $127 million as a private company with several strategic investors including...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|